Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
Giuseppe Curigliano(European Institute of Oncology), B. Xu(Henan University of Traditional Chinese Medicine), Marleen Kok(The Netherlands Cancer Institute), Meredith M. Regan(Dana-Farber Cancer Institute), Florian Fitzal, Mykola Anikusko(Sonnenhalde (Switzerland)), Sara Y. Brucker(University Children's Hospital Tübingen), F. Cardoso, Philip Poortmans(University of Antwerp), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Prudence A. Francis(Peter MacCallum Cancer Centre), Nadia Harbeck(Breast Center), B. Gulluoglu(Sonnenhalde (Switzerland)), L.A Carey(Dana-Farber Cancer Institute), Carsten Denkert(Philipps University of Marburg), Maria João Cardoso(Champalimaud Foundation), Stefan Aebi(University of Lucerne), J. Cortes(Harvard University), Jana de Boniface(Karolinska Institutet), Gerd Fastner(Dana-Farber Cancer Institute), Harold J. Burstein(Dana-Farber Cancer Institute), Hervé Bonnefoi, Beat Thürlimann(University of St.Gallen), Meteb Al‐Foheidi(Sonnenhalde (Switzerland)), Jens Huober(University of St.Gallen), Jonas Bergh(Karolinska Institutet), Charlotte E. Coles(University of Cambridge), A.V. Barrio, Stephen Chia(BC Cancer Agency), William P. Weber(University of Basel), Suzette Delaloge(Institut Gustave Roussy), William J. Gradishar(Northwestern University), A. DeMichele, Sibylle Loibl(Goethe University Frankfurt), Carlos Caldas(University of Cambridge), Orit Kaidar‐Person(Dana-Farber Cancer Institute), Carlos H. Barrios(Eastern Cooperative Oncology Group), Daniela Morales(Universidade Federal do Rio Grande do Sul), H Gamal(Sonnenhalde (Switzerland)), R. Badwe(Dana-Farber Cancer Institute), Zeping Jiang, Chien Shiun Huang, Fabrice André(Inserm), Jörg Heil(Harvard University), David Cameron(Corewell Health), Oreste Gentilini(San Raffaele University of Rome)
Cited by 218
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k